Antihyperglycemics (sulfonylureas)
- Stimulate insulin release regardless glucose
- Cheap + effective A1c lowering
- Main cost: hypoglycemia + weight gain
- Glipizide often favored in CKD
- Glyburide → more/prolonged hypoglycemia
- No cardiorenal outcome advantage
- Often displaced by safer modern drugs
Class at a glance
- Stimulate insulin release regardless glucose
Practical pearls
- Often displaced by safer modern drugs
Clinical role
- Cheap + effective A1c lowering
- Glipizide often favored in CKD
- Glyburide → more/prolonged hypoglycemia
Members / distinctions
- Main cost: hypoglycemia + weight gain
- No cardiorenal outcome advantage
Pearls
- Many experts advise against glyburide
Self-check
- What do Antihyperglycemics (sulfonylureas) stimulate?
Insulin release regardless glucose. - Which sulfonylurea causes more prolonged hypoglycemia?
Glyburide.
Drugs in this class (4)
Antihyperglycemics (sulfonylureas) prescription history
Animated chart of estimated U.S. prescriptions per year, Diabetes meds (1923–2026). Sulfonylurea highlighted from 1957.
All drug classes · Open Antihyperglycemics (sulfonylureas) in the interactive console ↗